Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
Aixin ShiPanpan XieLasse Lykke NielsenTrine Vang SkjøthXuemei HeSine Pfeiffer HaugaardPublished in: Advances in therapy (2020)
ClinicalTrials.gov, identifier NCT03288740.